Literature DB >> 20615827

Sentinel lymph node biopsy in selected cases of ductal carcinoma in situ.

María Vicenta Collado1, Jaime Ruiz-Tovar, Augusto García-Villanueva, Roberto Rojo, Lucía Latorre, María Eugenia Rioja, Fernando González-Palacios.   

Abstract

INTRODUCTION: Axillary lymphadenectomy is nowadays not recommended to treat ductal carcinoma in situ (DCIS), but there is controversy surrounding the indication for sentinel lymph node biopsy (SLNB).
MATERIALS AND METHODS: A prospective study of a selected group of patients diagnosed preoperatively with DCIS was performed between 2004 and 2009. Indications for SLNB were histologically determined high-grade tumours, tumour size >2 cm and patients scheduled to undergo a mastectomy.
RESULTS: Sixty-five patients were analysed. Surgical technique was mastectomy in 39 patients (60%) and conservative breast surgery in 26 (40%). Definitive histological study of the resected breast tumour revealed 43 cases (66.2%) of DCIS, 15 (23.1%) of ductal invasive carcinoma and seven (10.7%) microinvasive tumours. In confirmed DCIS, only 6.9% of sentinel lymph nodes were positive, in microinvasive carcinoma 28.5% and in invasive carcinoma 40% were positive. Total number of patients with positive sentinel lymph nodes was 11 (16.9%). Of 39 mastectomies, 12 corresponded to microinvasive or invasive carcinoma and six (50%) showed a positive SLNB.
CONCLUSIONS: Performing SLNB avoids an unnecessary second surgery to study axillary lymph nodes in invasive carcinoma diagnosed after definitive histological study. In patients undergoing a mastectomy, this study requires an axillary lymphadenectomy that is not useful in up to 50% of cases. We think that in a selected group of patients with DCIS, SLNB improves tumour staging, adapts the treatment and avoids second surgery in this group of patients.

Entities:  

Mesh:

Year:  2010        PMID: 20615827     DOI: 10.1007/s12094-010-0543-3

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  14 in total

Review 1.  Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19-22, 2001, Philadelphia, Pennsylvania.

Authors:  Gordon F Schwartz; Armando E Giuliano; Umberto Veronesi
Journal:  Cancer       Date:  2002-05-15       Impact factor: 6.860

2.  [Consensus meeting on selective biopsy of the sentinel node in breast cancer. Spanish Society of Senology and Breast Disease].

Authors:  A Piñero; J Giménez; B Merck; C Vázquez
Journal:  Rev Esp Med Nucl       Date:  2007 May-Jun

Review 3.  Controversies in the use of sentinel nodes: microinvasion, post surgery and after preoperative systemic treatment.

Authors:  Paolo Veronesi; Julia Rodriguez-Fernandez; Mattia Intra
Journal:  Breast       Date:  2007-08-13       Impact factor: 4.380

4.  Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ.

Authors:  Tina W F Yen; Kelly K Hunt; Merrick I Ross; Nadeem Q Mirza; Gildy V Babiera; Funda Meric-Bernstam; S Eva Singletary; W Fraser Symmans; Sharon H Giordano; Barry W Feig; Frederick C Ames; Henry M Kuerer
Journal:  J Am Coll Surg       Date:  2005-04       Impact factor: 6.113

Review 5.  Ductal carcinoma in situ: value of sentinel lymph node biopsy.

Authors:  Rita Sakr; Emmanuel Barranger; Martine Antoine; Herve Prugnolle; Emile Daraï; Serge Uzan
Journal:  J Surg Oncol       Date:  2006-10-01       Impact factor: 3.454

6.  [Benefit of sentinel node biopsy in patients with breast ductal carcinoma in situ].

Authors:  Isabel T Rubio; Isabel Roca; Dolors Sabadell; Jordi Xercavins
Journal:  Cir Esp       Date:  2009-02-05       Impact factor: 1.653

7.  Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer.

Authors:  Wendie A Berg; Lorena Gutierrez; Moriel S NessAiver; W Bradford Carter; Mythreyi Bhargavan; Rebecca S Lewis; Olga B Ioffe
Journal:  Radiology       Date:  2004-10-14       Impact factor: 11.105

8.  Sentinel node biopsy is not a standard procedure in ductal carcinoma in situ of the breast: the experience of the European institute of oncology on 854 patients in 10 years.

Authors:  Mattia Intra; Nicole Rotmensz; Paolo Veronesi; Marco Colleoni; Simona Iodice; Giovanni Paganelli; Giuseppe Viale; Umberto Veronesi
Journal:  Ann Surg       Date:  2008-02       Impact factor: 12.969

Review 9.  Ductal carcinoma in situ: biology, diagnosis, and new therapies.

Authors:  Marcia Valenzuela; Thomas B Julian
Journal:  Clin Breast Cancer       Date:  2007-08       Impact factor: 3.225

10.  Sentinel node procedure is warranted in ductal carcinoma in situ with high risk of occult invasive carcinoma and microinvasive carcinoma treated by mastectomy.

Authors:  Christine Tunon-de-Lara; Sylvia Giard; Max Buttarelli; Jérome Blanchot; Jean-Marc Classe; Marc Baron; Brice Monnier; Gilles Houvenaeghel
Journal:  Breast J       Date:  2008 Mar-Apr       Impact factor: 2.431

View more
  3 in total

1.  Present and future of sentinel lymph node biopsy in breast cancer staging.

Authors:  A Piñero
Journal:  Clin Transl Oncol       Date:  2010-07       Impact factor: 3.405

2.  Sentinel lymph node biopsy in patients with ductal carcinoma in situ: systematic review and meta-analysis.

Authors:  Matthew G Davey; Colm O'Flaherty; Eoin F Cleere; Aoife Nohilly; James Phelan; Evan Ronane; Aoife J Lowery; Michael J Kerin
Journal:  BJS Open       Date:  2022-03-08

3.  Basal cytokeratin as a potential marker of low risk of invasion in ductal carcinoma in situ.

Authors:  Fernando N Aguiar; Henrique N Mendes; Cinthya S Cirqueira; Carlos E Bacchi; Filomena M Carvalho
Journal:  Clinics (Sao Paulo)       Date:  2013-05       Impact factor: 2.365

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.